title: In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.
abstract: Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complete remission, 2 patients had a partial remission and the other 2 were resistant.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Sergio
authors.initials: S
authors.lastname: Rutella
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Voso
authors.forename: Luana
authors.initials: L
authors.lastname: Fianchi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Scardocci
authors.forename: Livio
authors.initials: L
authors.lastname: Pagano
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D004359:Drug Therapy, Combination; D000079982:Gemtuzumab; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000276:immunology; D010865:Pilot Projects
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000922:Immunotoxins; D016179:Granulocyte Colony-Stimulating Factor; D000079982:Gemtuzumab